Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Plos One|January 30, 2010
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccineSandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, et al.
The Journal of Infectious Diseases|April 3, 2019
Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 InfectionMatt A Price, Wasima Rida, William Kilembe, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Plos One|February 7, 2009
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern AfricaEtienne Karita, Nzeera Ketter, Matt A Price, et al.
The Journal of Infectious Diseases|October 3, 2017
Evaluating the Impact of Functional Genetic Variation on HIV-1 ControlPaul J McLaren, Sara L Pulit, Deepti Gurdasani, et al.
Science Immunology|November 11, 2018
Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1Lies Boelen, Bisrat Debebe, Marcos Silveira, et al.
Nature Medicine|May 17, 2016
Impact of pre-adapted HIV transmissionJonathan M Carlson, Victor Y Du, Nico Pfeifer, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
Vaccine|April 29, 2008
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East AfricaWalter Jaoko, Frederick N Nakwagala, Omu Anzala, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
Pageof 18